secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001178913-23-000670
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab reports FY2022 net loss of $27.6M; cash runway through March 2024
--------------------------------------------------------------------------

- Net loss of $27.6M in 2022 vs $12.5M in 2021; R&D expenses rose 168% to $17.0M.
- Cash used in operations was $20.4M; cash, equivalents and deposits fund operations through March 31, 2024.
- Phase 2 PSC trial actively recruiting; added 20mg/kg dose arm and open-label extension.
- Phase 2 SSc trial planned for H1 2023; completed NASH trial met safety endpoint with encouraging biomarker activity.
- No revenue from product sales; accumulated deficit of $64M at Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891323000670/0001178913-23-000670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891323000670/zk2329164.htm
  HTML page:      https://secwatch.observer/filing/0001178913-23-000670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer